Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Mortality Rates Improve for Patients with Rheumatoid Arthritis

Mary Beth Nierengarten  |  Issue: October 2014  |  October 1, 2014

She also says, though, that recent research suggests that people with RA may age at an accelerated rate compared with those without RA, adding fuel to the need for early aggressive treatment.

“The systemic inflammation that characterizes RA puts people with the disease at risk of accelerated aging and early mortality,” she says. “Early, aggressive treatment is our best means of addressing these risks.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Mary Beth Nierengarten is a freelance medical journalist based in St. Paul, Minn.

References

  1. Norton S, et al. Excess mortality in rheumatoid arthritis: Gains in life expectancy over 25 years. BSR. 2014; Abstract O34.
  2. Humphreys JH, Warner A, Chipping J. Mortality trends in patients with early rheumatoid arthritis over 20 years: Results from the Norfolk Arthritis Register. Arthritis Care Res (Hoboken). 2014 Sep;66(9):1296–1301.

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsDrug UpdatesResearch RheumRheumatoid Arthritis Tagged with:mortality rateNierengartenPainpatient careResearchRheumatoid arthritissurvivalTreatment

Related Articles

    Do Bisphosphonates Reduce Cardiovascular-Related Mortality?

    May 13, 2021

    It is well known that hip fractures are associated with significant morbidity and mortality: Mortality increases 15–25% in the year following a hip fracture.1–5 We know that treating osteo­porosis prevents fractures and improves patient survival. But is there a relationship beyond this? Several studies have found that bisphosphonate therapy is associated with a reduction in…

    RA Shortens Life Expectancy of Patients with RA & Increases Healthcare Costs

    April 27, 2021

    RA shortens life expectancy, even with advances in treatment—and more so for women than for men, according to new research by Chiu et al.

    Studies Say People with Rheumatic Disease Face Work Challenges

    September 11, 2020

    EULAR 2020 e-CONGRESS—People with rheumatic diseases have more difficulty than others leading a work life, and researchers are attempting to quantify just how long they are able to remain healthy and working compared with the general population. This topic is particularly pressing because people are now expected to work for a longer and longer periods…

    Studies Highlight Risk of Damage from Lupus Treatments

    April 20, 2017

    WASHINGTON, D.C.—Conference goers who braved the final day of the 2016 ACR/ARHP Annual Meeting were awarded for their stamina by learning about issues relating to the damage caused by systemic lupus erythematosus (SLE) during the session Systemic Lupus Erythematosus—Clinical Aspects and Treatment V: Damage and Morbidity. Minimizing Damage: Early Use of GC-Sparing Strategies Jayne Little,…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences